Selective plasma exchange in ABO-incompatible kidney transplantation: comparison of substitution with albumin and partial substitution with fresh frozen plasma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 01 2020
29 01 2020
Historique:
received:
29
04
2019
accepted:
13
01
2020
entrez:
31
1
2020
pubmed:
31
1
2020
medline:
14
7
2020
Statut:
epublish
Résumé
We have performed selective plasma exchange (SePE) as apheresis before ABO-incompatible kidney transplantation since 2015. In this study, we divided the SePE sessions into two groups, those using albumin alone (Group A) and those partially using fresh frozen plasma (FFP) (Group F), and compared their clinical efficacies. A total of 58 sessions of SePE (Group A: n = 41, Group F: n = 17) were performed in 30 recipients of ABOi kidney transplantation during the study period and the decrease in isoagglutinin titers, changes in the levels of serum IgG and IgM as well as coagulation factors (fibrinogen, factor XIII), and incidence of side effects were retrospectively compared. There was a more significant decrease of isoagglutinin titers in Group F compared to Group A. Immunoglobulins and coagulants were replenished in Group F. Meanwhile, the incidence of side effects was significantly higher in Group F. SePE using FFP, which can effectively decrease isoagglutinins titers and replenish immunoglobulin and coagulation factors, may be a beneficial treatment modality as apheresis before ABO-incompatible kidney transplantation, in spite of a disadvantage that there are many side effects.
Identifiants
pubmed: 31996738
doi: 10.1038/s41598-020-58436-2
pii: 10.1038/s41598-020-58436-2
pmc: PMC6989510
doi:
Substances chimiques
ABO Blood-Group System
0
Isoantibodies
0
Serum Albumin, Human
ZIF514RVZR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1434Références
Gloor, J. & Stegall, M. ABO-incompatible kidney transplantation with and without splenectomy. Transplantation 82, 720, https://doi.org/10.1097/01.tp.0000229428.03414.b2 (2006).
pubmed: 16969303
doi: 10.1097/01.tp.0000229428.03414.b2
Shin, E. et al. Long-term Outcomes of ABO-Incompatible Living Donor Kidney Transplantation: A Comparative Analysis. Transplant Proc 47, 1720–1726, https://doi.org/10.1016/j.transproceed.2015.05.026 (2015).
pubmed: 26293040
doi: 10.1016/j.transproceed.2015.05.026
Sonnenday, C. J. et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 4, 1315–1322, https://doi.org/10.1111/j.1600-6143.2004.00507.x (2004).
pubmed: 15268734
doi: 10.1111/j.1600-6143.2004.00507.x
Uchida, J. et al. Excellent outcomes of ABO-incompatible kidney transplantation: a single-center experience. Transplant Proc 44, 204–209, https://doi.org/10.1016/j.transproceed.2011.11.006 (2012).
pubmed: 22310615
doi: 10.1016/j.transproceed.2011.11.006
Wilpert, J. et al. Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. Nephrol Dial Transplant 25, 3778–3786, https://doi.org/10.1093/ndt/gfq229 (2010).
pubmed: 20466677
doi: 10.1093/ndt/gfq229
Yabu, J. M. & Fontaine, M. J. ABO-incompatible living donor kidney transplantation without post-transplant therapeutic plasma exchange. J Clin Apher 30, 340–346, https://doi.org/10.1002/jca.21390 (2015).
pubmed: 25739580
pmcid: 4561032
doi: 10.1002/jca.21390
Lipshutz, G. S. et al. ABO blood type-incompatible kidney transplantation and access to organs. Arch Surg 146, 453–458, https://doi.org/10.1001/archsurg.2011.40 (2011).
pubmed: 21502455
doi: 10.1001/archsurg.2011.40
Montgomery, R. A. et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 87, 1246–1255, https://doi.org/10.1097/TP.0b013e31819f2024 (2009).
pubmed: 19384174
doi: 10.1097/TP.0b013e31819f2024
Scurt, F. G. et al. Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis. Lancet 393, 2059–2072, https://doi.org/10.1016/S0140-6736(18)32091-9 (2019).
pubmed: 31006573
doi: 10.1016/S0140-6736(18)32091-9
Segev, D. L. et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 5, 2570–2575, https://doi.org/10.1111/j.1600-6143.2005.01031.x (2005).
pubmed: 16162210
doi: 10.1111/j.1600-6143.2005.01031.x
Toki, D. et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am J Transplant 9, 567–577, https://doi.org/10.1111/j.1600-6143.2008.02538.x (2009).
pubmed: 19260836
doi: 10.1111/j.1600-6143.2008.02538.x
Warren, D. S. & Montgomery, R. A. Incompatible kidney transplantation: lessons from a decade of desensitization and paired kidney exchange. Immunol Res 47, 257–264, https://doi.org/10.1007/s12026-009-8157-y (2010).
pubmed: 20087679
doi: 10.1007/s12026-009-8157-y
Abu Jawdeh, B. G., Cuffy, M. C., Alloway, R. R., Shields, A. R. & Woodle, E. S. Desensitization in kidney transplantation: review and future perspectives. Clin Transplant 28, 494–507, https://doi.org/10.1111/ctr.12335 (2014).
pubmed: 24621089
doi: 10.1111/ctr.12335
Rostaing, L. et al. Treatment of large plasma volumes using specific immunoadsorption to desensitize ABO-incompatible kidney-transplant candidates. J Nephropathol 5, 90–97, https://doi.org/10.15171/jnp.2016.17 (2016).
pubmed: 27540536
pmcid: 4961822
doi: 10.15171/jnp.2016.17
Singh, N., Pirsch, J. & Samaniego, M. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev (Orlando) 23, 34–46, https://doi.org/10.1016/j.trre.2008.08.004 (2009).
doi: 10.1016/j.trre.2008.08.004
Hanafusa, N. et al. The effect of different apheresis modalities on coagulation factor XIII level during antibody removal in ABO-blood type incompatible living related renal transplantation. Transfus Apher Sci 49, 254–258, https://doi.org/10.1016/j.transci.2013.06.004 (2013).
pubmed: 23827327
doi: 10.1016/j.transci.2013.06.004
Kim, Y. C. et al. The effect of desensitization therapy in kidney transplantation. Clin Exp Nephrol 22, 179–187, https://doi.org/10.1007/s10157-017-1424-7 (2018).
pubmed: 28634772
doi: 10.1007/s10157-017-1424-7
Takahashi, K. & Saito, K. ABO-incompatible kidney transplantation. Transplant Rev (Orlando) 27, 1–8, https://doi.org/10.1016/j.trre.2012.07.003 (2013).
doi: 10.1016/j.trre.2012.07.003
Basic-Jukic, N. et al. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial 9, 391–395, https://doi.org/10.1111/j.1744-9987.2005.00319.x (2005).
pubmed: 16202013
doi: 10.1111/j.1744-9987.2005.00319.x
Song, E. Y. et al. Establishment of a national on-line registry for apheresis in Korea. Transfus Apher Sci 38, 93–100, https://doi.org/10.1016/j.transci.2008.01.007 (2008).
pubmed: 18359274
doi: 10.1016/j.transci.2008.01.007
de Weerd, A. E. et al. ABO-incompatible kidney transplant recipients have a higher bleeding risk after antigen-specific immunoadsorption. Transpl Int 28, 25–33, https://doi.org/10.1111/tri.12412 (2015).
pubmed: 25070762
doi: 10.1111/tri.12412
Ohkubo, A. & Okado, T. Selective plasma exchange. Transfus Apher Sci 56, 657–660, https://doi.org/10.1016/j.transci.2017.08.010 (2017).
pubmed: 28939369
doi: 10.1016/j.transci.2017.08.010
Kawabe, M. et al. Successful treatment of myeloma cast nephropathy using bortezomib-based chemotherapy plus selective plasma exchange. CEN Case Rep 5, 232–237, https://doi.org/10.1007/s13730-016-0231-4 (2016).
pubmed: 28508984
pmcid: 5411651
doi: 10.1007/s13730-016-0231-4
Nakae, H., Fukuda, H., Okuyama, M. & Igarashi, T. Selective Plasma Exchange for Critically Ill Patients Accompanied With Thrombocytopenia. Ther Apher Dial 20, 339–341, https://doi.org/10.1111/1744-9987.12464 (2016).
pubmed: 27523072
doi: 10.1111/1744-9987.12464
Nasu, K., Hanafusa, N. & Nangaku, M. Selective plasma exchange can reduce auto-antibodies in patients with bullous pemphigoid without affecting factor XIII and fibrinogen. J Clin Apher 32, 589–591, https://doi.org/10.1002/jca.21513 (2017).
pubmed: 27709645
doi: 10.1002/jca.21513
Ohkubo, A. et al. Removal kinetics of antibodies against glutamic acid decarboxylase by various plasmapheresis modalities in the treatment of neurological disorders. Ther Apher Dial 18, 231–237, https://doi.org/10.1111/1744-9987.12209 (2014).
pubmed: 24965288
doi: 10.1111/1744-9987.12209
Hanaoka, A. et al. Efficacy of selective plasma exchange as pre-transplant apheresis in ABO-incompatible kidney transplantation. Renal Replacement Therapy 5, https://doi.org/10.1186/s41100-019-0204-0 (2019).
Kim, M. H. et al. Risk factors for postoperative bleeding in ABO-incompatible kidney transplantation. Clin Transplant 29, 365–372, https://doi.org/10.1111/ctr.12525 (2015).
pubmed: 25646784
doi: 10.1111/ctr.12525
Morath, C. et al. ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption. Transplantation 93, 827–834, https://doi.org/10.1097/TP.0b013e31824836ae (2012).
pubmed: 22382504
doi: 10.1097/TP.0b013e31824836ae
Tyden, G. et al. Implementation of a Protocol for ABO-incompatible kidney transplantation–a three-center experience with 60 consecutive transplantations. Transplantation 83, 1153–1155, https://doi.org/10.1097/01.tp.0000262570.18117.55 (2007).
pubmed: 17496528
doi: 10.1097/01.tp.0000262570.18117.55
Uchida, J. et al. Acute Cellular Rejection in ABO-Incompatible Renal Transplant Recipients Receiving Rituximab Is Associated with Delayed-Onset Neutropenia. Ann Transplant 22, 455–462 (2017).
pubmed: 28740069
doi: 10.12659/AOT.902236
Liese, J. G., Wintergerst, U., Tympner, K. D. & Belohradsky, B. H. High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child 146, 335–339 (1992).
pubmed: 1543181
Quartier, P. et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 134, 589–596 (1999).
pubmed: 10228295
doi: 10.1016/S0022-3476(99)70246-5
Miyamoto, S. et al. Removal Dynamics of Immunoglobulin and Fibrinogen by Conventional Plasma Exchange, Selective Plasma Exchange, and a Combination of the Two. Ther Apher Dial 20, 342–347, https://doi.org/10.1111/1744-9987.12465 (2016).
pubmed: 27523073
doi: 10.1111/1744-9987.12465
Ohkubo, A. et al. Solute removal capacity of high cut-off membrane plasma separators. Ther Apher Dial 17, 484–489, https://doi.org/10.1111/1744-9987.12114 (2013).
pubmed: 24107276
doi: 10.1111/1744-9987.12114
Ohkubo, A. et al. Fibrinogen Reduction During Selective Plasma Exchange due to Membrane Fouling. Ther Apher Dial 21, 232–237, https://doi.org/10.1111/1744-9987.12564 (2017).
pubmed: 28661096
doi: 10.1111/1744-9987.12564